218 related articles for article (PubMed ID: 32669450)
1. Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies.
Kiltz U; Wei JC; van der Heijde D; van den Bosch F; Walsh JA; Boonen A; Gensler LS; Hunter T; Carlier H; Dong Y; Li X; Bolce R; Strand V; Braun J
J Rheumatol; 2021 Feb; 48(2):188-197. PubMed ID: 32669450
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
[TBL] [Abstract][Full Text] [Related]
3. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results.
Deodhar AA; Mease PJ; Rahman P; Navarro-Compán V; Strand V; Hunter T; Bolce R; Leon L; Lauzon S; Marzo-Ortega H
BMC Rheumatol; 2021 Sep; 5(1):35. PubMed ID: 34538257
[TBL] [Abstract][Full Text] [Related]
4. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
[TBL] [Abstract][Full Text] [Related]
5. Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial.
Walsh JA; Magrey MN; Baraliakos X; Inui K; Weng MY; Lubrano E; van der Heijde D; Boonen A; Gensler LS; Strand V; Braun J; Hunter T; Li X; Zhu B; León L; Calderon DMS; Kiltz U
Arthritis Care Res (Hoboken); 2022 Mar; 74(3):451-460. PubMed ID: 33044756
[TBL] [Abstract][Full Text] [Related]
6. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
van der Horst-Bruinsma IE; de Vlam K; Walsh JA; Bolce R; Hunter T; Sandoval D; Zhu D; Geneus V; Soriano ER; Magrey M
Adv Ther; 2022 Jun; 39(6):2806-2819. PubMed ID: 35429281
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
Deodhar A; Poddubnyy D; Pacheco-Tena C; Salvarani C; Lespessailles E; Rahman P; Järvinen P; Sanchez-Burson J; Gaffney K; Lee EB; Krishnan E; Santisteban S; Li X; Zhao F; Carlier H; Reveille JD;
Arthritis Rheumatol; 2019 Apr; 71(4):599-611. PubMed ID: 30343531
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.
Braun J; Kiltz U; Deodhar A; Tomita T; Dougados M; Bolce R; Sandoval D; Lin CY; Walsh J
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35853675
[TBL] [Abstract][Full Text] [Related]
9. Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis.
Mease P; Walsh JA; Baraliakos X; Inman R; de Vlam K; Wei JC; Hunter T; Gallo G; Sandoval D; Zhao F; Dong Y; Bolce R; Marzo-Ortega H
Rheumatol Ther; 2019 Sep; 6(3):435-450. PubMed ID: 31254223
[TBL] [Abstract][Full Text] [Related]
10. Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
Xue Y; Hu J; Liu D; Li J; Wu H; Tan C; Dai L; Sun L; Li Z; Xiao Z; Huang C; Yan Y; Ji F; Chen R; Zou H
BioDrugs; 2024 Jan; 38(1):145-156. PubMed ID: 37737952
[TBL] [Abstract][Full Text] [Related]
11. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).
Landewé RB; Gensler LS; Poddubnyy D; Rahman P; Hojnik M; Li X; Liu Leage S; Adams D; Carlier H; Van den Bosch F;
Ann Rheum Dis; 2021 Aug; 80(8):1022-1030. PubMed ID: 33958326
[TBL] [Abstract][Full Text] [Related]
12. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Deodhar A; van der Heijde D; Gensler LS; Kim TH; Maksymowych WP; Østergaard M; Poddubnyy D; Marzo-Ortega H; Bessette L; Tomita T; Leung A; Hojnik M; Gallo G; Li X; Adams D; Carlier H; Sieper J;
Lancet; 2020 Jan; 395(10217):53-64. PubMed ID: 31813637
[TBL] [Abstract][Full Text] [Related]
13. Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials.
Kiltz U; van der Heijde D; Boonen A; Gensler LS; Gibble TH; Guo J; Carlier H; Braun J
J Rheumatol; 2023 Jun; 50(6):754-762. PubMed ID: 36725056
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
Sieper J; van der Heijde D; Dougados M; Mease PJ; Maksymowych WP; Brown MA; Arora V; Pangan AL
Ann Rheum Dis; 2013 Jun; 72(6):815-22. PubMed ID: 22772328
[TBL] [Abstract][Full Text] [Related]
16. Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis.
Maksymowych WP; Baraliakos X; Lambert RG; Landewé R; Sandoval D; Carlier H; Lisse J; Li X; Hojnik M; Østergaard M
Lancet Rheumatol; 2022 Sep; 4(9):e626-e634. PubMed ID: 38288892
[TBL] [Abstract][Full Text] [Related]
17. Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial.
Deodhar A; Mease P; Rahman P; Navarro-Compán V; Marzo-Ortega H; Hunter T; Sandoval D; Kronbergs A; Leon L; Shan M; Leung A; De Vlam K; Strand V
Rheumatol Ther; 2021 Mar; 8(1):135-150. PubMed ID: 33284423
[TBL] [Abstract][Full Text] [Related]
18. Ixekizumab for treating ankylosing spondylitis.
Kiwalkar S; Beier S; Deodhar A
Immunotherapy; 2019 Oct; 11(15):1273-1282. PubMed ID: 31530049
[TBL] [Abstract][Full Text] [Related]
19. Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks.
Marzo-Ortega H; Mease PJ; Rahman P; Navarro-Compán V; Strand V; Dougados M; Combe B; Wei JC; Baraliakos X; Hunter T; Sandoval D; Li X; Zhu B; Bessette L; Deodhar A
Rheumatol Ther; 2020 Dec; 7(4):759-774. PubMed ID: 32814997
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab: in non-radiographic axial spondyloarthritis.
Burness CB; Deeks ED
Drugs; 2012 Dec; 72(18):2385-95. PubMed ID: 23231024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]